Company intelligence / Profile preview

Rottapharm Biotech

Monza, Lombardy, Italyrottapharmbiotech.com ↗

Ownership: Private
Employees: ~100
Development stage: Other

Overview

Rottapharm Biotech focuses on innovative drug discovery and development in rheumatology, oncology, pain management, infectious diseases, and advanced therapies. Its lead programs include vorbipiprant (an EP4 antagonist) in Phase I/II trials for metastatic gastrointestinal cancers and CR10049 as a first-in-class kinase inhibitor targeting inflammatory osteoarthritis. The company has also developed a DNA vaccine against COVID‑19 with Takis. Historical strengths include the invention of glucosamine sulfate formulations for osteoarthritis.

Therapeutic areas: NeurologyInfectious DiseasesOncologyImmunologyRheumatology
Modalities: Small moleculeMonoclonal antibodyDNA vaccineProtein
Industry: Biotech

Partnerships

Takiscollaborations with academic spin-offs and external biotech companiesSelvita

Beyond the preview

Go deeper on Rottapharm Biotech.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Rottapharm Biotech.